Dendreon Downgraded by JMP Securities (DNDN)
Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for more data” on its Provenge for…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for more data” on its Provenge for the treatment of late-stage prostate cancer. It was back around April 11 that JMP downgraded the shares to an Outperform rating. Shares are trading down about 3% at $6.62 in pre-market trading.
Jon C. Ogg
May 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Contact [email protected] for any questions or corrections.







